Optimizing Abiraterone (Zytiga) Therapy by Exploring the Relation Between an Early Biomarker ‐ Drug Exposure ‐ as a Predictor for Drug Response in Patients With mCRPC
Phase of Trial: Phase I/II
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Abiraterone acetate (Primary)
- Indications Prostate cancer
- Focus Pharmacokinetics
- Acronyms OPTIMUM
- 07 Jun 2017 Biomarkers information updated
- 30 Mar 2017 Planned End Date changed from 1 Mar 2017 to 1 Mar 2018.
- 30 Mar 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2018.